Research Article

Impaired Fasting Glucose and Diabetes as Predictors for Radial Artery Calcification in End Stage Renal Disease Patients

Katarzyna Janda, 1 Marcin Krzanowski, 1 Mariusz Gajda, 2 Paulina Dumnicka, 3 Danuta Fedak, 4 Grzegorz J. Lis, 2 Piotr Jaśkowski, 1 Jan A. Litwin, 2 and Władysław Sułowicz 1

1 Chair and Department of Nephrology, Jagiellonian University Medical College, 31-501 Krakow, Poland
2 Chair and Department of Histology, Jagiellonian University Medical College, 31-501 Krakow, Poland
3 Department of Medical Diagnostics, Jagiellonian University Medical College, 31-501 Krakow, Poland
4 Chair of Clinical Biochemistry, Jagiellonian University Medical College, 31-501 Krakow, Poland

Correspondence should be addressed to Władysław Sułowicz; wladsul@mp.pl

Received 10 August 2013; Revised 15 November 2013; Accepted 19 November 2013

Academic Editor: Umberto Campia

Copyright © 2013 Katarzyna Janda et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. The objective of the study was to assess the relationship between selected clinical and biochemical parameters of end stage renal disease (ESRD) patients and arterial calcification. Materials and Methods. The study comprised 59 stage 5 chronic kidney disease patients (36 hemodialyzed and 23 predialysis). The examined parameters included common carotid artery intima-media thickness (CCA-IMT), BMI, incidence of diabetes and impaired fasting glucose (IFG), dyslipidemia, hypertension, and 3-year mortality. Plasma levels asymmetric dimethylarginine (ADMA), osteopontin (OPN), osteoprotegerin (OPG), and osteocalcin (OC) were also measured. Fragments of radial artery obtained during creation of hemodialysis access were stained for calcifications using von Kossa method and alizarin red. Results. Calcification of radial artery was significantly associated with higher prevalence of IFG and diabetes ($P = 0.0004$) and older age ($P = 0.003$), as well as higher OPG ($P = 0.014$) and ADMA concentrations ($P = 0.022$). Fasting glucose $> 5.6$ mmol/l (IFG and diabetes) significantly predicted vascular calcification in multiple logistic regression. The calcification was also associated with higher CCA-IMT ($P = 0.006$) and mortality ($P = 0.004$; OR for death 5.39 [1.20–24.1] after adjustment for dialysis status and age). Conclusion. Combination of renal insufficiency and hyperglycemic conditions exerts a synergistic effect on vascular calcification and increases the risk of death.

1. Introduction

Vascular calcification is an active process similar to the mineralization that occurs in bone [1, 2]. Vascular smooth muscle cells undergo phenotypic differentiation into osteoblast-like or chondroblast-like cells and they synthesize calcification regulating proteins and matrix components typically found in bone and in cartilage [3, 4]. Calcification of the arterial media, observed even in small vessels (Mönckeberg’s calcification), is common in uremic patients and seems to be less associated with inflammation as compared to intimal mineralization typical for atherosclerosis [5, 6].

Vascular mineralization advances with age and is intensified in diabetes, dyslipidemia, chronic kidney disease, and hypertension. In newly treated hemodialysis and peritoneal dialysis patients, diabetes, dialysis duration, and the previous presence of aortic arch calcification (AAC) accelerate further progression of AAC (an important risk factor for cardiovascular complications) [7]. Hyperinsulinemia and insulin resistance (clinical signs of type 2 diabetes) are positively correlated with the arterial calcification [8, 9]. Arterial medial calcifications often occur also in diabetic individuals as a component of the diabetic macroangiopathy. In the animal model, insulin resistance induced in rats by fructose feeding resulted in increased aortic calcium deposition, elevated calcium-phosphate index, and local hyperplastic changes in the aortic media [10].

Blood vessels obtained from end stage renal disease (ESRD) patients were often studied by various histological techniques to assess vascular calcification. They were...
collected during renal transplantation (epigastric or iliac arteries) or by peripheral arterial biopsy (radial artery) [3, II, 12].

In the present study we used small samples (otherwise routinely discarded) of radial arterial walls obtained during creation of arteriovenous fistula for hemodialysis access. The study was aimed at investigating the relationship between selected clinical and biochemical parameters, with special emphasis on diabetes markers, and the level of histologically assessed radial artery calcification in end stage renal disease patients.

2. Materials and Methods

2.1. Patients. The study population consisted of 59 patients (38 males, 21 female; mean age at the beginning of the study 61 ± 16 yrs), including 36 on maintenance hemodialysis (HD) and 23 on predialysis (stage 5 of CKD). The study was approved by the Bioethics Committee of the Jagiellonian University and all patients signed an informed consent for their participation. The data on mortality was collected over a period of three years. During this period, all the patients were treated at the Department of Nephrology, Jagiellonian University Hospital. The mortality data, including the causes of death, was based on the patients’ records.

2.2. Laboratory Tests. In all patients, selected biochemical parameters were assessed: serum concentrations of total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides (TG), serum creatinine, peripheral blood counts, albumin, glucose, intact parathyroid hormone (iPTH), total calcium (Ca) and phosphate (Pi), high sensitive C-reactive protein (hsCRP), asymmetric dimethylarginine (ADMA), osteopontin (OPN), osteoprotegerin (OPG), and osteocalcin (OC). Homeostasis Model of Assessment-Insulin Resistance (HOMA-IR) was calculated by application of the international formula: fasting insulin (µIU/mL) × fasting glucose (mmol/L)/22.5 [13].

Routine biochemical tests were carried out using automatic biochemical analyzers: Hitachi 917 (Hitachi, Japan) and Modular P (Roche Diagnostics, Mannheim, Germany). Concentrations of hsCRP were measured using immunonephelometric method on Nephelometer BN II (Siemens Healthcare Diagnostics, Germany). Hematological parameters were measured using Sysmex XE 2100 Hematological Analyzer (Sysmex Corp., Japan).

OPN, OC, OPG, and ADMA were determined using ELISA microplate immunoassays and ELX808 automatic reader (BIO-TEK Instruments, Inc., Vermont, USA). The following kits of reagents were applied: OPN (R&D Systems), OC (METRA, Germany), OPG (QUIDEL, BioVendor, Czech Republic), and ADMA (Immundiagnostik, Germany).

The mean arterial pressure (MAP) was calculated according to the formula: MAP = DBP + 1/3(SBP-DBP), where SBP is systolic blood pressure and DBP is diastolic blood pressure.

The intima-media thickness of the common carotid artery trunk (CCA-IMT) was assessed by ultrasonography (B presentation, Acuson 128 XP/10 apparatus equipped with a linear head at 5/7 MHz). The measurements were performed bilaterally at 0.5 cm and 2 cm below the division of the common carotid artery during diastolic phase of the heart cycle. The results were expressed as the arithmetic means of the values obtained for the left and right arteries.

2.3. Histology. Fragments of radial artery, approx. 5 × 2 mm in size, were collected during the first creation of arteriovenous fistula for hemodialysis access. The samples were immediately immersed in 10% phosphate-buffered formalin and fixed overnight and then rinsed in PBS and soaked in 30% sucrose. The material was snap-frozen and tissue blocks were positioned in a cryostat for cutting sections in a plane encompassing the entire thickness of the vascular wall. Serial 10 µm-thick cryosections were cut and thaw-mounted on poly-L-lysine coated slides. Sections were stained routinely with Mayer’s haematoxylin and eosin (HE), with von Kossa method and with alizarin red. The stained sections were examined using an Olympus BX-50 microscope (Olympus, Tokyo, Japan) in brightfield mode and images were registered using Olympus DP-71 digital CCD camera controlled by Olympus AnalySIS FIVE software. The advancement of vascular calcification was semiquantitatively evaluated in von Kossa and alizarin red-stained sections by two independent observers. The degree of mineralization was classified according to the following scale: 0: no mineral content, 1: a few small dispersed concretions, 2: numerous small dispersed concretions, 3: larger granular concretions, and 4: large areas occupied by fused mineral deposits. The reproducibility of the morphological analysis was confirmed by Bland-Altman method and by calculating intraclass correlation coefficient (ICC) which was 0.88.

2.4. Statistical Methods. The number of patients (percentage of the group) was reported for categorical variables and mean ± standard deviation or median (lower-upper quartile) for continuous variables, depending on distribution. The Shapiro-Wilk test was used to assess normality. Contingency tables were analyzed with Pearson chi-squared test. Student t-test or Mann-Whitney test was used for simple comparisons between the groups. Multiple logistic regression models were constructed using the variables that differed significantly between the groups in simple comparisons and/or predefined sets of confounders, as pointed in the results. Odds ratios (OR) for 1 unit increase with 95% confidence intervals (95% CI) being reported, unless otherwise stated. All tests were two-tailed and the results were considered statistically significant at P ≤ 0.05. Statistica 10 software (StatSoft, Tulsa, OK, USA) was used for computations.

3. Results

3.1. Histology. Routine histology (HE) showed general morphology of the radial artery, with intimal thickening in the vast majority of the examined specimens (Figure 1(a)). Basophilic deposits were visible in arterial wall in cases of very intense calcification (Figure 1(b)). The preliminary comparison of two staining methods used for the assessment
of the mineralization degree showed that von Kossa method was less sensitive; thus we employed alizarin red staining for further analysis and for correlation of the vascular calcification level with clinical and biochemical data.

Morphologically, mineral deposits were found in all layers of the arterial wall but they were most frequently localized in the media (Figures 1(b)–1(d)). In less advanced lesions, deposits were preferentially located close to the outer and inner elastic laminae (Figure 1(e)). Some deposits were fine and dispersed (Figure 1(f)), while others occupied larger areas and in the most advanced cases even the entire thickness of the media (Figures 1(b)–1(d)). Only very scanty mineral deposits were occasionally seen in the vascular intima.

Among 59 radial artery samples examined histologically, 34 showed positive alizarin red staining indicative of the calcification process. The proportion of samples with arterial wall mineralization (Table 1) as well as its advancement (Figure 2(a)) did not differ between HD and predialysis patients ($P = 0.6$). In further analysis, HD patients were studied together with predialysis patients; nevertheless all multiple regression models were adjusted for HD status.

3.2. Biochemical and Clinical Data. Table 1 summarizes differences in clinical and biochemical parameters between the groups with and without calcifications as assessed by alizarin red staining.
Table 1: Differences in clinical parameters between patients with and without vascular calcifications as assessed by alizarin red staining of the radial artery.

|                                  | Patients with vascular calcifications (grades 1–4, N = 34) | Patients without vascular calcifications (grades 0, N = 25) | P  |
|----------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|----|
| Male gender, N (%)              | 23 (68%)                                                  | 15 (60%)                                                  | NS |
| HD treatment, N (%)             | 21 (62%)                                                  | 15 (60%)                                                  | NS |
| HD duration, months\(^a\)       | 10 (3–36)                                                 | 6 (1–38)                                                  | NS |
| Hemoglobin, g/dL                | 10.7 ± 1.6                                                | 11.5 ± 1.9                                                | NS |
| Albumin, g/L                    | 40.3 ± 4.2                                                | 41.5 ± 6.1                                                | NS |
| Age, years                       | 66 ± 15                                                   | 54 ± 14                                                   | 0.003 |
| Active smoking, N (%)           | 10 (29%)                                                  | 7 (28%)                                                   | NS |
| BMI, kg/m\(^2\)                 | 26.1 ± 5.6                                                | 26.4 ± 6.1                                                | NS |
| Diabetes, N (%)                 | 18 (53%)                                                  | 1 (4%)                                                    | 0.0001 |
| Type 1 diabetes, N (%)          | 2 (6%)                                                    | 0                                                         | NS  |
| Type 2 diabetes, N (%)          | 16 (47%)                                                  | 1 (4%)                                                    | 0.0002 |
| IFG, N (%)                      | 3 (9%)                                                    | 3 (12%)                                                   | NS  |
| SBP, mmHg                        | 138 ± 19                                                  | 146 ± 18                                                  | NS  |
| DBP, mmHg                        | 82 ± 9                                                    | 86 ± 11                                                   | NS  |
| MAP, mmHg                        | 101 ± 12                                                  | 106 ± 12                                                  | 0.045 |
| Fasting glucose, mmol/L         | 5.7 (4.9–7.9)                                             | 4.8 (4.6–5.2)                                             | 0.022 |
| Insulin, \(\mu\)U/mL\(^b\)     | 7.60 (5.85–18.89)                                         | 9.88 (6.12–13.50)                                         | NS  |
| HOMA-IR\(^b\)                   | 1.68 (1.20–4.44)                                          | 1.89 (1.32–3.12)                                          | NS  |
| CRP, mg/L                       | 8.81 (2.19–24.3)                                          | 4.86 (3.06–9.82)                                          | NS  |
| ADMA, \(\mu\)mol/L             | 0.86 ± 0.22                                               | 0.72 ± 0.16                                               | 0.022 |
| Ca, mmol/L                      | 2.18 ± 0.16                                               | 2.25 ± 0.27                                               | NS  |
| Pi, mmol/L                      | 1.50 (1.34–1.79)                                          | 1.41 (1.21–1.86)                                          | NS  |
| Ca × Pi, mmol\(^2\)/L\(^2\)    | 3.15 (2.88–3.77)                                          | 3.31 (2.86–3.91)                                          | NS  |
| iPTH, pg/mL                     | 213 (179–512)                                             | 290 (230–428)                                             | NS  |
| OPG, pmol/L                     | 9.36 (5.93–12.38)                                         | 5.10 (2.40–7.70)                                          | 0.014 |
| OPN, ng/mL                      | 310 (208–559)                                             | 304 (217–377)                                             | NS  |
| OC, ng/mL                       | 41.7 (31.7–69.5)                                          | 42.0 (23.9–56.0)                                          | NS  |
| CCA-IMT, mm                      | 0.98 ± 0.13                                               | 0.86 ± 0.14                                               | 0.006 |
| All-cause mortality, N (%)      | 13 (38%)                                                  | 3 (12%)                                                   | 0.004 |
| Cardiovascular mortality, N (%) | 13 (38%)                                                  | 3 (12%)                                                   | 0.025 |

\(^a\) Data for the group of HD patients only (21 patients with calcifications and 15 patients without calcifications).

\(^b\) Data for nondiabetic patients only (16 patients with calcifications and 24 patients without calcifications).

red staining of radial artery. Vascular calcification was associated with higher age of patients, higher glucose, and diabetes. MAP was slightly lower in patients with calcifications and the levels of ADMA and OPG were higher in this group.

Clinical criteria of the metabolic syndrome [14, 15] were compared between patients with and without vascular calcifications in radial artery (Table 2). Among patients with vascular calcifications, the number of individuals with fasting glucose level above 5.6 mmol/L, that is, patients with IFG (prediabetes) [16] and diabetes, was significantly higher \((P = 0.0004)\). Moreover, vascular calcifications were more severe in the group of patients with IFG and diabetes (Figure 2(b)). Other criteria of the metabolic syndrome did not differ between the groups with or without calcifications.

The association of radial artery calcifications with IFG and diabetes was further confirmed by multiple logistic regression (Table 3). Three models were constructed, containing age and fasting glucose > 5.6 mmol/L as independent variables: the first one was adjusted for gender, HD status, and Ca × Pi product, and the second was additionally adjusted for dyslipidemia, hypertension, high BMI, and hsCRP. The third model, adjusted as the first one, included other variables that were significantly associated with arterial calcification in simple comparisons, that is, MAP, ADMA, and OPG. Fasting glucose > 5.6 mmol/L was the only variable independently associated with the vascular calcifications in all three models. The results were similar when diabetes was substituted for increased fasting glucose level in the models: OR = 17.2 (1.79–166); \(P = 0.011\) in model 1; OR = 25.4 (1.74–372); \(P = 0.015\) in model 2; OR = 24.6 (1.45–419); \(P = 0.022\) in model 3.

Patients with calcifications in radial arteries presented higher CCA-IMT (Table 1). The relation between CCA-IMT...
and histologically detected vascular calcification remained significant after adjustment for dialysis status, gender, Ca × Pi, hsCRP, and the presence of metabolic syndrome (OR for vascular calcification 2.31 per 0.1 mm increase in CCA-IMT; 95% CI 1.18–4.52; \(P = 0.011\)) but not after adjustment for age. CCA-IMT was significantly higher in patients with IFG and diabetes (0.98 ± 0.13 versus 0.88 ± 0.15 mm; \(P = 0.007\)).

Sixteen patients with calcifications in the radial artery (47%) died during 3 years of the followup, while in the group without calcifications the mortality was lower: 3 deaths (12%). All except 3 deaths occurred due to cardiovascular causes (Table 1). Vascular calcification was significantly associated with patients' mortality in simple analysis (\(P = 0.004\)) and after adjustment for HD status and age (OR for death 5.39; 95% CI 1.20–24.1; \(P = 0.024\)).

4. Discussion

This study presents a comprehensive comparison of biochemical and clinical data with the calcification status assessed histologically in the peripheral arteries of ESRD patients. Biopsies of radial artery collected during the creation of vascular access for hemodialysis were used previously by other authors to study calcification. However, in that study, the surgical anastomosis was performed in an end-to-end fashion; thus a sample encompassing the entire circumference of the artery could be excised and used for further analysis, allowing for a more reliable assessment of the calcification extent in the arterial wall [12].

In the study mentioned above, the authors found mineral deposits in 37% of the examined radial arteries. After adopting stringent morphological criteria to include even the finest calcifications and using more sensitive alizarin red staining for calcium detection we found arterial calcification in 57% of cases.

Calcification can develop in two distinct layers of the artery: intima and media [17]. Intimal calcification occurs in advanced atherosclerotic lesions and is associated with lipid accumulation and infiltration of the inflammatory cells, such as macrophages and T cells. Medial arterial calcification (MAC) displays features very similar to those of physiological calcification in bone [18]. MAC develops independently of atherosclerosis and is a commonly observed pathology in diabetes, ESRD, and ageing [17].

The present study revealed a significant association of arterial medial calcifications with impaired fasting glucose (IFG, prediabetes) and diabetes but not with other criteria of the metabolic syndrome including overweight. Our results are in accordance with the study of Lim et al. [19] demonstrating the relationship between anthropometric parameters, metabolic profiles, and coronary artery calcium scoring (CACS). Subjects with IFG or diabetes had higher CACS and more advanced coronary stenosis than normal subjects. Moreover, several studies confirmed that fasting plasma glucose is a better independent determinant of the progression of coronary artery calcification than the other metabolic syndrome risk factors [20–22].

The above mentioned papers presented a relationship between hyperglycemia and vascular calcification based on noninvasive imaging of blood vessels. In our study, this relationship was analyzed for the first time using histologically examined samples of peripheral arteries.

Hyperglycemia is an established risk factor for cardiovascular disease. Our study showed that fasting hyperglycemia, mostly associated with type 2 diabetes, was the only significant predictor of vascular calcifications in ESRD patients. Consistently, type 2 diabetes was associated with more severe
Table 2: Differences in clinical criteria of the metabolic syndrome between patients with and without vascular calcifications as assessed by alizarin red staining of the radial artery.

|                                | Patients with vascular calcifications (grades 1–4, N = 34) | Patients without vascular calcifications (grades 0, N = 25) | P    |
|--------------------------------|----------------------------------------------------------|----------------------------------------------------------|------|
| BMI > 25 kg/m² (overweight or obesity), N (%) | 18 (53%)                                                  | 14 (56%)                                                  | NS   |
| Fasting glucose > 5.6 mmol/L (IFG or diabetes), N (%) | 21 (62%)                                                  | 4 (16%)                                                   | 0.0004|
| Hypertension, N (%)             | 28 (82%)                                                  | 23 (92%)                                                  | NS   |
| Low HDL⁴, N (%)                 | 13 (38%)                                                  | 7 (28%)                                                   | NS   |
| High TG (>1.7 mmol/L), N (%)    | 15 (44%)                                                  | 12 (48%)                                                  | NS   |
| Three or more of above criteria present, N (%) | 20 (59%)                                                  | 9 (36%)                                                   | NS   |

⁴Low HDL cholesterol (<1.0 mmol/L in men, <1.3 mmol/L in women).

Table 3: Multiple logistic regression models to study the associations of the selected variables with vascular calcifications as assessed by alizarin red staining of the radial artery.

|                                | Model 1a | Model 2b | Model 3a |
|--------------------------------|----------|----------|----------|
| OR (95% CI)                    | P        | OR (95% CI) | P        | OR (95% CI) | P        |
| Age, years                     | 1.05 (0.99–1.10) | NS | 1.05 (0.99–1.11) | NS | 1.00 (0.93–1.08) | NS |
| Fasting glucose > 5.6 mmol/L   | 8.24 (1.66–40.9) | **0.008** | 14.8 (1.68–130) | **0.012** | 23.8 (1.84–309) | **0.012** |
| MAP, mmHg                      | —        | —        | —        | —        | 0.93 (0.86–1.02) | NS   |
| ADMA, 0.1 μmol/L               | —        | —        | —        | —        | 1.66 (0.70–3.92) | NS   |
| OPG, pmol/L                    | —        | —        | —        | —        | 1.16 (0.92–1.45) | NS   |

Odds ratios for positive staining are presented.

⁴Adjusted for gender, dialysis status of patients, and Ca × Pi.

⁵Adjusted for the parameters of the metabolic syndrome: low HDL cholesterol (<1.0 mmol/L in men, <1.3 mmol/L in women), high triglycerides (>1.7 mmol/L), and high BMI (≥25 kg/m²), as well as hypertension, CRP, gender, dialysis status of patients, and Ca × Pi.

Bold font: statically significant data.

calcification. Recent evidence suggests that medial calcification in diabetes is an active, cell-mediated process, similar to that observed in patients with end stage renal disease [23, 24].

Vascular calcifications and atherosclerosis are frequent in patients with ESRD and they are associated with increased cardiovascular morbidity [25]. Coronary artery calcification (CAC) was found in 70.2% of dialysis patients and was significantly associated with CCA-IMT and the thickness of atherosclerotic plaques [26]. These results indicate that both, medial calcification and atherosclerotic lesions, frequently coexist in patients with ESRD and that CCA-IMT, increased in patients with calcifications examined in this study, may serve as a surrogate marker of vascular calcification.

The mechanisms responsible for vascular calcification include inflammation and oxidative stress, as well as bone and mineral metabolism disturbances. In our study higher ADMA and OPG levels were associated with vascular calcification. High ADMA levels are associated with endothelial dysfunction and cardiovascular damage [27]. Serum levels of ADMA in chronic kidney disease increase due to its defective inactivation and excretion. Coen at al. [28] postulated that ADMA may play a role in the pathogenesis of vascular calcification in dialysis patients. Increased serum OPG is associated with type 2 diabetes, chronic kidney disease, and the severity of vascular calcification and coronary artery disease [29–31].

It could represent a compensatory mechanism for vascular damage, also showing a protective effect against vascular calcification [32, 33].

Arterial calcification was associated with higher mortality in ESRD patients. According to our knowledge, the relationship between vascular calcification assessed histologically and the long-term mortality in chronic kidney disease patients has not yet been studied. Ogawa et al. [34] examined the effect of CT-assessed aortic arch calcification on mortality in the 401 hemodialysis patients during 4-year follow-up period and demonstrated that cardiovascular mortality was significantly higher in patients with calcification. In our study, employing a different assessment model (radial artery and histology) this effect of arterial calcification on mortality in ESRD patients has been confirmed.

5. Conclusions

Small samples of radial artery obtained during creation of vascular access for hemodialysis may successfully serve as source of the material for histological assessment of vascular mineralization. In end stage renal disease patients, impaired fasting glucose (prediabetes) and diabetes predict vascular calcification which is significantly associated with higher mortality. These results indicate that combination of
renal insufficiency and hyperglycemic conditions exerts a synergistic effect on vascular calcification and increases the risk of death.

**Conflict of Interests**

The authors have no conflict of interests to declare.

**Acknowledgments**

The authors are grateful to all the patients who participated in this study. All of the authors have no relevant conflict of interests. Sources of Funding: Financial support was provided by statutory Grants K/ZDS/000597 and K/ZDS001453 from the Jagiellonian University Medical College to Katarzyna Janda and Władysław Sulowicz. The paper has not been published elsewhere.

**References**

[1] E. Neven, S. Dauwe, M. E. De Broe, P. C. D’Haese, and V. Persy, “Endochondral bone formation is involved in media calcification in rats and in men,” *Kidney International*, vol. 72, no. 5, pp. 574–581, 2007.

[2] J. L. Reynolds, A. J. Joannides, J. N. Skepper et al., “Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD,” *Journal of the American Society of Nephrology*, vol. 15, no. 11, pp. 2857–2867, 2004.

[3] P. Ballanti, G. Silvestrini, S. Pisanò et al., “Medial artery calcification of uremic patients: a histological, histochemical and ultrastructural study,” *Histology and Histopathology*, vol. 26, no. 2, pp. 191–200, 2011.

[4] N. Nguyen, V. Naik, and M. Y. Speer, “Diabetes mellitus accelerates cartilaginous metaplasia and calcification in atherosclerotic vessels of LDLr mutant mice,” *Cardiovascular Pathology*, vol. 22, no. 2, pp. 167–175, 2013.

[5] K. Amann, “Media calcification and intima calcification are distinct entities in chronic kidney disease,” *Clinical Journal of the American Society of Nephrology*, vol. 3, no. 6, pp. 1599–1605, 2008.

[6] M. A. Hofmann Bowman and E. M. McNally, “Genetic pathways of vascular calcification,” *Trends in Cardiovascular Medicine*, vol. 22, no. 4, pp. 93–98, 2012.

[7] H. G. Kim, S. W. Song, T. Y. Kim, and Y. O. Kim, “Risk factors for progression of aortic arch calcification in patients on maintenance hemodialysis and peritoneal dialysis,” *Hemodialysis International*, vol. 15, no. 4, pp. 460–467, 2011.

[8] L. Chhabra, B. Liti, G. Kuraganti, S. Kaul, and N. Trivedi, “Challenges in the management of type 2 diabetes mellitus and cardiovascular risk factors in obese subjects: what is the evidence and what are the myths?” *International Journal of Endocrinology*, vol. 2013, Article ID 856793, 10 pages, 2013.

[9] J. C. Kovacik and V. Fuster, “Vascular calcification, diabetes, and cardiovascular disease: connecting the dots,” *JACC: Cardiovascular Imaging*, vol. 5, no. 4, pp. 367–369, 2012.

[10] Y.-B. Zhou, J. Zhang, Y. Cai et al., “Insulin resistance induces medial artery calcification in fructose-fed rats,” *Experimental Biology and Medicine*, vol. 237, no. 1, pp. 50–57, 2012.

[11] G. Schlieper, A. Aretz, S. C. Verberckmoes et al., “Ultrastructural analysis of vascular calcifications in uremia,” *Journal of the American Society of Nephrology*, vol. 21, no. 4, pp. 689–696, 2010.

[12] N. Wang, J. Yang, X. Yu et al., “Radial artery calcification in end-stage renal disease patients is associated with deposition of osteopontin and diminished expression of α-smooth muscle actin,” *Nephrology*, vol. 13, no. 5, pp. 367–375, 2008.

[13] J. C. Levy, D. R. Matthews, and M. P. Hermans, “Correct homeostasis model assessment (HOMA) evaluation uses the computer program,” *Diabetes Care*, vol. 21, no. 12, pp. 2191–2192, 1998.

[14] K. G. Alberti, R. H. Eckel, S. M. Grundy et al., “Harmonizing the metabolic syndrome,” *Circulation*, vol. 120, no. 16, pp. 1640–1645, 2009.

[15] K. G. Alberti, P. Z. Zimmet, J. Shaw, and S. M. Grundy, “The metabolic syndrome,” International Diabetes Federation, pp. 1–24, 2006.

[16] Y. S. Levitzky, M. J. Pencina, R. B. D’Agostino et al., “Impact of impaired fasting glucose on cardiovascular disease: the Framingham Heart Study,” *Journal of the American College of Cardiology*, vol. 51, no. 3, pp. 264–270, 2008.

[17] R. C. Johnson, J. A. Leopold, and J. Loscalzo, “Vascular calcification,” *Circulation Research*, vol. 99, pp. 1044–1059, 2006.

[18] J. Janzen and P. N. Vuong, “Arterial calcifications: morphological aspects and their pathological implications,” *Zeitschrift fur Kardiologie*, vol. 90, no. 6, pp. 61–110, 2001.

[19] S. Lim, S. H. Choi, E.-K. Choi et al., “Comprehensive evaluation of coronary arteries by multidetector-row cardiac computed tomography according to the glucose level of asymptomatic individuals,” *Atherosclerosis*, vol. 205, no. 1, pp. 156–162, 2009.

[20] C. K. Kramer, D. Von Mühlén, J. L. Gross, G. A. Laughlin, and E. Barrett-Connor, “Blood pressure and fasting plasma glucose rather than metabolic syndrome predict coronary artery calcification: the Rancho Bernardo Study,” *Diabetes Care*, vol. 32, no. 1, pp. 141–146, 2009.

[21] S. Moebus, A. Stang, S. Möhlenkamp et al., “Association of impaired fasting glucose and coronary artery calcification as a marker of subclinical atherosclerosis in a population-based cohort-results of the Heinz Nixdorf Recall Study,” *Diabetologia*, vol. 52, no. 1, pp. 81–89, 2009.

[22] K. Nasir, R. D. Santos, K. Tufail et al., “High-normal fasting blood glucose in non-diabetic range is associated with increased coronary artery calcium burden in asymptomatic men,” *Atherosclerosis*, vol. 195, no. 2, pp. 155–160, 2007.

[23] N. X. Chen and S. M. Moe, “Arterial calcification in diabetes,” *Current Diabetes Reports*, vol. 3, no. 1, pp. 28–32, 2003.

[24] N. Sakata, K. Takeuchi, K. Noda et al., “Calcification of the medial layer of the internal thoracic artery in diabetic patients: relevance of glycoxidation,” *Journal of Vascular Research*, vol. 40, no. 6, pp. 567–574, 2003.

[25] W. G. Petchey, C. M. Hawley, D. W. Johnson, B. A. Haluska, T. W. Watkins, and N. M. Isbel, “Multimodality vascular imaging in CKD: divergence of risk between measured parameters,” *Nephrology Dialysis Transplantation*, vol. 27, pp. 1004–1012, 2012.

[26] I. Kurnatowska, P. Grzelak, L. Stefanczyk, and M. Nowicki, “Tight relations between coronary calcification and atherosclerotic lesions in the carotid artery in chronic dialysis patients,” *Nephrology*, vol. 15, no. 2, pp. 184–189, 2010.

[27] G. Bouras, S. Deftereos, D. Tousoulis et al., “Asymmetric dimethylarginine (ADMA): a promising biomarker for cardiovascular disease?” *Current Topics in Medicinal Chemistry*, vol. 13, pp. 180–200, 2013.
[28] G. Coen, D. Mantella, D. Sardella et al., "Asymmetric dimethylarginine, vascular calcifications and parathyroid hormone serum levels in hemodialysis patients," *Journal of Nephrology*, vol. 22, no. 5, pp. 616–622, 2009.

[29] B. Akinci, A. Celtik, F. Yuksel et al., "Increased osteoprotegerin levels in women with previous gestational diabetes developing metabolic syndrome," *Diabetes Research and Clinical Practice*, vol. 91, no. 1, pp. 26–31, 2011.

[30] D. T. Ashley, E. P. O'Sullivan, C. Davenport et al., "Similar to adiponectin, serum levels of osteoprotegerin are associated with obesity in healthy subjects," *Metabolism*, vol. 60, no. 7, pp. 994–1000, 2011.

[31] K. Janda, M. Krzanowski, E. Chowaniec et al., "Osteoprotegerin as a marker of cardiovascular risk in patients on peritoneal dialysis," *Polskie Archiwum Medycyny Wewnętrznej*, vol. 123, pp. 149–155, 2013.

[32] B. J. Bennett, M. Scatena, E. A. Kirk et al., "Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 28, no. 9, pp. 2117–2124, 2006.

[33] P. A. Price, H. H. June, J. R. Buckley, and M. K. Williamson, "Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 21, no. 10, pp. 1610–1616, 2001.

[34] T. Ogawa, H. Ishida, M. Akamatsu et al., "Progression of aortic arch calcification and all-cause and cardiovascular mortality in chronic hemodialysis patients," *International Urology and Nephrology*, vol. 42, no. 1, pp. 187–194, 2010.
